Prof. Dr. Wolfram-Hubertus Zimmermann
The majority of patients with heart failure present severe structural and functional cardiac impairments with limited responsiveness to classical pharmacological treatment. These patients may benefit from reconstruction of functional myocardium using stem cell-based tissue engineering. The Institute of Pharmacology employs state-of-the-art concepts from pharmacology and biomedical engineering to establish proof-of-concept and translate individualized tissue engineered heart repair.
Tissue engineering enables us to build three-dimensional culture systems with organotypic structure and function. Additional development of different organ surrogates to simulate disease processes and develop novel therapeutics for organ protection and regeneration is ongoing at the Institute of Pharmacology. The availability of stem cells from individual patients creates the opportunity to devise novel pharmacological, gene-based, and cell-based approaches for individualized treatments in patients with heart failure, skeletal muscle disease, and neurological disorders.